Argent BioPharma Limited (ASX:RGT)
Australia · Delayed Price · Currency is AUD 0.0320
+0.0020 (6.67%)
Sep 4, 2026, 3:58 PM AEST
Argent BioPharma Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 0.14 | 1.02 | 0.7 | 0.24 | 1.89 |
Cash & Short-Term Investments | 0.14 | 1.02 | 0.7 | 0.24 | 1.89 |
Cash Growth | -86.19% | 45.75% | 193.08% | -87.29% | -65.28% |
Accounts Receivable | 0 | 0.07 | 0.14 | 0.21 | 0.74 |
Other Receivables | 0.24 | 0.31 | 0.34 | 0.32 | 1.2 |
Receivables | 0.24 | 0.38 | 0.48 | 0.53 | 1.94 |
Inventory | - | 0.13 | 0.88 | 1.36 | 1.84 |
Prepaid Expenses | 0.08 | 0.5 | 0.69 | 0.4 | 0.8 |
Total Current Assets | 0.46 | 2.03 | 2.74 | 2.53 | 6.46 |
Property, Plant & Equipment | 0.1 | 0.44 | 6.72 | 7.45 | 8.8 |
Long-Term Investments | 0.73 | - | 1.33 | - | 0.16 |
Goodwill | - | - | - | - | 3.15 |
Total Assets | 1.29 | 2.47 | 10.79 | 9.98 | 18.56 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 0.76 | 1.81 | 0.96 | 2.19 | 2.52 |
Accrued Expenses | 0.3 | 0.32 | 0.35 | 0.54 | 0.69 |
Short-Term Debt | 7.38 | 7.93 | 8.68 | 9.18 | 2.1 |
Current Portion of Leases | 0.01 | 0.11 | 0.22 | 0.19 | 0.28 |
Current Unearned Revenue | - | - | 0.55 | 0.66 | 1.81 |
Other Current Liabilities | 0.09 | 0.66 | 1.42 | 0.58 | 0.31 |
Total Current Liabilities | 8.54 | 10.83 | 12.18 | 13.33 | 7.71 |
Long-Term Debt | 2.15 | - | - | - | - |
Long-Term Leases | 0.05 | 0.25 | 0.82 | 0.38 | 1.97 |
Long-Term Unearned Revenue | - | - | 3.6 | 4.28 | 3.68 |
Other Long-Term Liabilities | - | 0.02 | 0.02 | 0.02 | 0.02 |
Total Liabilities | 10.74 | 11.1 | 16.61 | 18.02 | 13.38 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 140.69 | 138.59 | 123.29 | 103.69 | 97.25 |
Retained Earnings | -155.22 | -147.51 | -129.67 | -119.17 | -98.35 |
Comprehensive Income & Other | 5.09 | 0.3 | 1.23 | 8.08 | 6.93 |
Total Common Equity | -9.45 | -8.63 | -5.15 | -7.4 | 5.84 |
Minority Interest | - | - | -0.67 | -0.63 | -0.66 |
Shareholders' Equity | -9.45 | -8.63 | -5.82 | -8.03 | 5.18 |
Total Liabilities & Equity | 1.29 | 2.47 | 10.79 | 9.98 | 18.56 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 9.59 | 8.29 | 9.72 | 9.75 | 4.35 |
Net Cash (Debt) | -9.45 | -7.26 | -9.02 | -9.51 | -2.47 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -0.11 | -0.13 | -0.24 | -3.23 | -0.96 |
Filing Date Shares Outstanding | 116.61 | 72.18 | 48.41 | 4.43 | 2.85 |
Total Common Shares Outstanding | 111.11 | 72.18 | 45.28 | 3.35 | 2.73 |
Working Capital | -8.08 | -8.8 | -9.44 | -10.8 | -1.25 |
Book Value Per Share | -0.09 | -0.12 | -0.11 | -2.21 | 2.14 |
Tangible Book Value | -9.45 | -8.63 | -5.15 | -7.4 | 2.69 |
Tangible Book Value Per Share | -0.09 | -0.12 | -0.11 | -2.21 | 0.99 |
Machinery | 0.14 | 0.95 | 9.79 | 10.04 | 9.07 |